PrimeVax is a clinical stage immuno-oncology company that is relentlessly dedicated to fighting cancer. They are pioneering the use of the Dengue Virus as an oncolytic virotherapy to combat late-stage cancers, offering a new approach to invoke a potent anti-cancer immune response while prioritizing safety. PrimeVax holds the world's only patent for cancer treatment using the dengue virus.

Their leading asset, PV001-DV, is a live, attenuated strain of the Dengue Virus with an exceptional balance of safety and immunogenicity. PV001-DV has been extensively studied in humans for over 20 years and has proven to be both safe and effective. Through an exclusive license with the U.

S. Army, PrimeVax has access to develop DENV-1 45AZ5 for all cancers worldwide. PrimeVax's approach is unique because their dengue virus is not genetically modified.

Instead, it safely induces a native anti-dengue immune response in humans, resulting in direct tumor killing and broad immunostimulatory effects. Their data has shown strong anti-tumor mechanisms across healthy volunteers and matching immune stimulation in cancer patients' blood samples. Currently, PrimeVax's focus is on melanoma, with ongoing Phase 1b and Phase 2 clinical trials for PD-1 refractory patients.

Additionally, they have preclinical studies in other solid tumors and are exploring combination therapies with checkpoint immunotherapies. PrimeVax is proud to collaborate with esteemed partners like the U. S.

Army, Rush University Medical Center, and others to advance their research and development. Their commitment to publishing lead papers and collaborative research showcases their dedication to transparency and scientific advancement in the field. For more information, please visit PrimeVax's website or contact them at info@primevax.

com